Literature DB >> 32975004

Selective N-Terminal BET Bromodomain Inhibitors by Targeting Non-Conserved Residues and Structured Water Displacement*.

Huarui Cui1, Anand Divakaran2, Anil K Pandey1, Jorden A Johnson1, Huda Zahid1, Zachariah J Hoell1, Mikael O Ellingson1, Ke Shi3, Hideki Aihara3, Daniel A Harki2, William C K Pomerantz1,2.   

Abstract

Bromodomain and extra-terminal (BET) family proteins, BRD2-4 and T, are important drug targets; however, the biological functions of each bromodomain remain ill-defined. Chemical probes that selectively inhibit a single BET bromodomain are lacking, although pan inhibitors of the first (D1), and second (D2), bromodomain are known. Here, we develop selective BET D1 inhibitors with preferred binding to BRD4 D1. In competitive inhibition assays, we show that our lead compound is 9-33 fold selective for BRD4 D1 over the other BET bromodomains. X-ray crystallography supports a role for the selectivity based on reorganization of a non-conserved lysine and displacement of an additional structured water in the BRD4 D1 binding site relative to our prior lead. Whereas pan-D1 inhibitors displace BRD4 from MYC enhancers, BRD4 D1 inhibition in MM.1S cells is insufficient for stopping Myc expression and may lead to its upregulation. Future analysis of BRD4 D1 gene regulation may shed light on differential BET bromodomain functions.
© 2020 Wiley-VCH GmbH.

Entities:  

Keywords:  BET bromodomains; BRD4 D1 selectivity; epigenetics; inhibitors; structure-activity relationships

Mesh:

Substances:

Year:  2020        PMID: 32975004      PMCID: PMC7855888          DOI: 10.1002/anie.202008625

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  32 in total

Review 1.  Translating the histone code.

Authors:  T Jenuwein; C D Allis
Journal:  Science       Date:  2001-08-10       Impact factor: 47.728

2.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

3.  PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.

Authors:  Kanak Raina; Jing Lu; Yimin Qian; Martha Altieri; Deborah Gordon; Ann Marie K Rossi; Jing Wang; Xin Chen; Hanqing Dong; Kam Siu; James D Winkler; Andrew P Crew; Craig M Crews; Kevin G Coleman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

4.  The cellular thermal shift assay for evaluating drug target interactions in cells.

Authors:  Rozbeh Jafari; Helena Almqvist; Hanna Axelsson; Marina Ignatushchenko; Thomas Lundbäck; Pär Nordlund; Daniel Martinez Molina
Journal:  Nat Protoc       Date:  2014-08-07       Impact factor: 13.491

5.  Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.

Authors:  Christopher R Wellaway; Paul Bamborough; Sharon G Bernard; Chun-Wa Chung; Peter D Craggs; Leanne Cutler; Emmanuel H Demont; John P Evans; Laurie Gordon; Bhumika Karamshi; Antonia J Lewis; Matthew J Lindon; Darren J Mitchell; Inmaculada Rioja; Peter E Soden; Simon Taylor; Robert J Watson; Rob Willis; James M Woolven; Beata S Wyspiańska; William J Kerr; Rab K Prinjha
Journal:  J Med Chem       Date:  2020-08-03       Impact factor: 7.446

6.  Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer.

Authors:  Jian Shi; Yifan Wang; Lei Zeng; Yadi Wu; Jiong Deng; Qiang Zhang; Yiwei Lin; Junlin Li; Tiebang Kang; Min Tao; Elena Rusinova; Guangtao Zhang; Chi Wang; Haining Zhu; Jun Yao; Yi-Xin Zeng; B Mark Evers; Ming-Ming Zhou; Binhua P Zhou
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

7.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

8.  Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor.

Authors:  Anand Divakaran; Siva K Talluri; Alex M Ayoub; Neeraj K Mishra; Huarui Cui; John C Widen; Norbert Berndt; Jin-Yi Zhu; Angela S Carlson; Joseph J Topczewski; Ernst K Schonbrunn; Daniel A Harki; William C K Pomerantz
Journal:  J Med Chem       Date:  2018-10-16       Impact factor: 7.446

9.  Click chemistry enables preclinical evaluation of targeted epigenetic therapies.

Authors:  Dean S Tyler; Johanna Vappiani; Tatiana Cañeque; Enid Y N Lam; Aoife Ward; Omer Gilan; Yih-Chih Chan; Antje Hienzsch; Anna Rutkowska; Thilo Werner; Anne J Wagner; Dave Lugo; Richard Gregory; Cesar Ramirez Molina; Neil Garton; Christopher R Wellaway; Susan Jackson; Laura MacPherson; Margarida Figueiredo; Sabine Stolzenburg; Charles C Bell; Colin House; Sarah-Jane Dawson; Edwin D Hawkins; Gerard Drewes; Rab K Prinjha; Raphaël Rodriguez; Paola Grandi; Mark A Dawson
Journal:  Science       Date:  2017-06-15       Impact factor: 47.728

10.  Fluorinated aromatic amino acids are sensitive 19F NMR probes for bromodomain-ligand interactions.

Authors:  Neeraj K Mishra; Andrew K Urick; Stuart W J Ember; Ernst Schönbrunn; William C Pomerantz
Journal:  ACS Chem Biol       Date:  2014-10-27       Impact factor: 5.100

View more
  7 in total

1.  New Design Rules for Developing Potent Cell-Active Inhibitors of the Nucleosome Remodeling Factor (NURF) via BPTF Bromodomain Inhibition.

Authors:  Huda Zahid; Caroline R Buchholz; Manjulata Singh; Michael F Ciccone; Alice Chan; Stanley Nithianantham; Ke Shi; Hideki Aihara; Marcus Fischer; Ernst Schönbrunn; Camila O Dos Santos; Joseph W Landry; William C K Pomerantz
Journal:  J Med Chem       Date:  2021-09-13       Impact factor: 8.039

2.  Development of an N-Terminal BRD4 Bromodomain-Targeted Degrader.

Authors:  Anand Divakaran; Cole R Scholtz; Huda Zahid; Wenwei Lin; Elizabeth C Griffith; Richard E Lee; Taosheng Chen; Daniel A Harki; William C K Pomerantz
Journal:  ACS Med Chem Lett       Date:  2022-09-29       Impact factor: 4.632

3.  Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development.

Authors:  Pan Tang; Jifa Zhang; Jie Liu; Cheng-Ming Chiang; Liang Ouyang
Journal:  J Med Chem       Date:  2021-02-22       Impact factor: 7.446

4.  Quantifying the Selectivity of Protein-Protein and Small Molecule Interactions with Fluorinated Tandem Bromodomain Reader Proteins.

Authors:  Prakriti Kalra; Logan McGraw; Jennifer R Kimbrough; Anil K Pandey; Jonathan Solberg; Huarui Cui; Anand Divakaran; Kristen John; Jon E Hawkinson; William C K Pomerantz
Journal:  ACS Chem Biol       Date:  2020-11-03       Impact factor: 5.100

5.  4-Methyl-1,2,3-Triazoles as N-Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Improved Selectivity.

Authors:  Huarui Cui; Angela S Carlson; Mary A Schleiff; Anand Divakaran; Jorden A Johnson; Caroline R Buchholz; Huda Zahid; Nora R Vail; Ke Shi; Hideki Aihara; Daniel A Harki; Grover P Miller; Joseph J Topczewski; William C K Pomerantz
Journal:  J Med Chem       Date:  2021-07-08       Impact factor: 8.039

6.  Endothelial p300 Promotes Portal Hypertension and Hepatic Fibrosis Through C-C Motif Chemokine Ligand 2-Mediated Angiocrine Signaling.

Authors:  Jinhang Gao; Bo Wei; Mengfei Liu; Petra Hirsova; Tejasav S Sehrawat; Sheng Cao; Xiao Hu; Fei Xue; Usman Yaqoob; Ningling Kang; Huarui Cui; William C K Pomerantz; Enis Kostallari; Vijay H Shah
Journal:  Hepatology       Date:  2021-04-19       Impact factor: 17.298

7.  Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis.

Authors:  Mengfei Liu; Sheng Cao; Li He; Jinhang Gao; Juan P Arab; Huarui Cui; Weixia Xuan; Yandong Gao; Tejasav S Sehrawat; Feda H Hamdan; Meritxell Ventura-Cots; Josepmaria Argemi; William C K Pomerantz; Steven A Johnsen; Jeong-Heon Lee; Fei Gao; Tamas Ordog; Philippe Mathurin; Alexander Revzin; Ramon Bataller; Huihuang Yan; Vijay H Shah
Journal:  Nat Commun       Date:  2021-07-27       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.